contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


asarina-pharma-applies-for-the-delisting-of-the-companys-shares

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Asarina Pharma

Stockholm, September 13, 2024. An extraordinary general meeting of Asarina Pharma AB (publ) ("Asarina" or the "Company") decided on August 21, 2024 that the Company shall enter into voluntary...

<div class="mfn-preamble"><p><strong>Stockholm, September 13, 2024. An extraordinary general meeting of Asarina Pharma AB (publ) ("Asarina" or the "Company") decided on August 21, 2024 that the Company shall enter into voluntary liquidation. In light of this, the Company's board has today decided to apply for the delisting of the Company's shares from the Nasdaq First North Growth Market in Stockholm.</strong></p></div><div class="mfn-body"><p>On 22 July 2024, Asarina published the board's proposal for an extraordinary general meeting to decide on voluntary liquidation of the Company. The proposal was submitted against the background that in mid-July 2024 the Company's partner process had not resulted in tenders for development collaborations or acquisition of the intangible assets related to Sepranolone, and that the conditions for a necessary capital raise for own development of Sepranolone were lacking. Since Asarina no longer conducts any operational activities, and that the Company's shareholders have decided on voluntary liquidation, the Company no longer meets the listing requirements on the Nasdaq First North Growth Market in Stockholm. The last day for trading in the Company's shares on Nasdaq First North Growth Market will be announced through a separate press release when the Company has received confirmation thereof from Nasdaq First North Growth Market.</p><p>Until the liquidation date, December 1, 2024, the Company's management and board will continue the work of finding buyers for Asarina's tangible and intangible assets.</p></div><div class="mfn-footer mfn-contacts mfn-c85405f73fa6"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Peter Nordkild, CEO<br>Tel.: +45 25 47 16 46<br>Email: peter.nordkild@asarinapharma.com<br>&nbsp;</p></div><div class="mfn-footer mfn-about mfn-6229831054f8"><p><strong class="mfn-heading-1">About Asarina Pharma</strong><br>Asarina Pharma AB (publ) is a Swedish biotechnology company. The company was founded in 2006 and the share has been traded since September 2018 on the Nasdaq First North Growth Market. Asarina Pharma AB (publ) is based in Solna. Asarina Pharma AB (publ) is listed on the Nasdaq First North Growth Market. The company thus follows the regulations that apply to First North. The company's Certified Adviser is Carnegie Investment Bank AB (publ).<br>&nbsp;<br>For further information see our website: www.asarinapharma.se.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/8464c251-f155-4e4a-bc7a-3df2c4ede9ed/asarina-pharma-applies-for-the-delisting-of-the-companys-shares.pdf" class="mfn-generated mfn-primary">Asarina Pharma applies for the delisting of the company's shares</a></p></div>

Asarina Pharma applies for the delisting of the company's shares

Return on capital (ROE, ROI, ROIC, RONIC)

What does negative working capital mean and why is it a good thing?

Drug development investment: Value creation through M&As and licensing agreements

Income statement

Amazon continues to grow in Sweden

Beställ vårt nyhetsbrev — inget användarkonto krävs!